Borje L.
- Country
- Sweden
- Department
- Dept of urology
Research Overview
- Phase 3 Randomized, Double-blind, Placebo-controlled Study of Apalutamide and GnRH Agonist in High-risk Localized or Locally Advanced Prostate Cancer with Primary Radiation Therapy
- Open-Label Extension Study on Long-Term Safety of Enzalutamide in Prostate Cancer Patients from Previous Clinical Trials
- Efficacy and Safety Evaluation of Enzalutamide and Leuprorelin Acetate in High-Risk Nonmetastatic Prostate Cancer Post-Definitive Therapy
Data & Insights
Has run more than one trial at 39 of 163 partner sites.
Specializations
Prostate Cancer Treatment
The investigator specializes in treating high-risk localized and locally advanced prostate cancer, with particular focus on therapeutic interventions for patients requiring targeted treatment approaches.
- Advanced hormone therapy applications
- Radiation therapy integration
- Novel therapeutic combinations
Their work encompasses evaluation of innovative treatment modalities for non-metastatic prostate cancer cases.
Therapeutic Innovation
The investigator focuses on developing and implementing advanced therapeutic strategies for prostate cancer management, particularly exploring combination treatments with hormone therapy.
- Long-term treatment outcomes
- Therapeutic safety profiles
- Clinical benefit assessment
Their expertise includes evaluating progressive treatment approaches for high-risk patients.
Diagnostic Imaging
The investigator utilizes advanced imaging techniques in prostate cancer assessment, including conventional and specialized PSMA-PET imaging for precise disease evaluation.
- Metastasis-free survival assessment
- Treatment response monitoring
- Disease progression evaluation
Their work integrates imaging technologies with therapeutic decision-making processes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.